28-day post-infusion data support KYV-101 safety profile KYV-101 is a novel, fully human CD19 CAR T-cell therapy designed for use in patients with B cell-driven autoimmune diseases The open-label, Phase 1 clinical trial in the U.S. is actively recruiting patients with LN at multiple…